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Key Points
• There was no differ-
ence in overall survival
after allogeneic trans-
plant between patients
aged 55-64 years and
patients $65 years.
• Age alone should not





The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin
lymphoma (NHL) patients $65 years in the United States is limited by lack of Medicare
coverage for this indication. Using the Center for International Blood and Marrow
Transplant Research (CIBMTR) database, we report allo-HCT outcomes of NHL patients aged
$65 years (older cohort; n 5 446) compared with a cohort of younger NHL patients aged
55-64 years (n5 1183). We identified 1629 NHL patients undergoing a first reduced-intensity
conditioning (RIC) or nonmyeloablative conditioning allo-HCT from 2008 to 2015 in the
United States. Cord blood or haploidentical transplants were excluded. The median age was
68 years (range 65-77) for the older cohort vs 60 years (range 55-64) in the younger cohort.
The 4-year adjusted probabilities of nonrelapse mortality (NRM), relapse/progression (R/P),
progression-free survival (PFS), and overall survival (OS) of the younger and older groups
were 24% vs 30% (P 5 .03), 41% vs 42% (P 5 .82), 37% vs 31% (P 5 .03), and 51% vs 46%
(P 5 .07), respectively. Using multivariate analysis, compared with the younger group,
the older cohort was associated with increased NRM, but there was no difference between
the 2 cohorts in terms of R/P, PFS, or OS. The most common cause of death was disease
relapse in both groups. In NHL patients eligible for allo-HCT, there was no difference in OS
between the 2 cohorts. Age alone should not determine allo-HCT eligibility in NHL, and
Medicare should expand allo-HCT coverage to older adults.
Submitted 12 March 2018; accepted 27 March 2018. DOI 10.1182/
bloodadvances.2018018531.
The full-text version of this article contains a data supplement.
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Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) is a
potentially curative option for patients with advanced high-risk
hematological malignancies. Despite its established effectiveness,
wider application of this procedure has been historically limited to
younger patients with few medical comorbidities. However, in the
last 2 decades, the advent and adoption of reduced-intensity
conditioning (RIC) or nonmyeloablative (NMA) regimens has led to
an increase in the number of allo-HCT procedures performed in the
United States, including increased utilization of this modality for
older patients or those with limiting medical comorbidities.1,2
The feasibility of allo-HCT with lower-intensity regimens is well
established in select older (age $65 years) patients. In a large
retrospective analysis of 372 patients aged 60-75 years (age $65
years, n 5 134) with various hematological malignancies undergoing
NMA allo-HCT, survival was not impacted by increasing patient age,
but rather by the presence of medical comorbidities, underscoring
the importance of assessing physiological age over an arbitrary
chronological age cutoff when determining allo-HCT eligibility.2
However, patients aged $65 years with certain hematological
malignancies (myelodysplastic syndrome [MDS], myeloma, myelofi-
brosis, or non-Hodgkin lymphoma [NHL]) with Medicare as primary
insurance in the United States, historically did not have coverage for
allo-HCT, leading to disparities in access between those with private
versus Medicare insurance. The Centers for Medicare and Medicaid
services (CMS) in the United States, as part of the national coverage
determination, may provide coverage of an item or service (eg, a
particular allo-HCT indication) only in the context of a clinical study
(ie, via the coverage with evidence development [CED] mechanism).
On 4 August 2010, using its CED mechanism, CMS established
coverage for allo-HCT for Medicare beneficiaries with MDS in an
ongoing Center for International Blood and Marrow Transplant
Research (CIBMTR) observational study comparing the outcomes of
patients aged 55-64 years vs those $65 years.3 Since that time,
other allo-HCT indications (myeloma, myelofibrosis, and sickle cell
disease) have also acquired CMS coverage, again only if performed
within the context of approved ongoing CIBMTR protocols.4
Unfortunately, allo-HCT is still not covered for NHL patients in the
United States according to current CMS guidelines,4 despite
the fact that the median age at diagnosis of NHL is 67 years in the
United States.5 This, combined with the fact that most patients
aged$65 years in the United States receive their primary insurance
coverage through Medicare (and most private insurance providers
follow CMS guidelines), means that the vast majority of NHL
patients lack access to this potentially curative treatment modality.
Although there is ample evidence that allo-HCT can provide long-
term disease control in select NHL patients in the frontline or
relapsed setting,6-13 most of these studies included only a small
subset of patients over the age of 65 years. For example, in the
study by Sorror et al,2 with 372 older patients, only ;25 patients
aged 65-75 years had lymphoma or myeloma. We report here a
registry analysis evaluating outcomes of US NHL patients aged
$65 years undergoing a RIC allo-HCT compared with a younger
cohort aged 55-64 years to determine whether the arbitrary age
cutoff is justifiable for those in need of this potentially lifesaving
procedure (younger cohort age cutoff being identical to the control
population age in the ongoing CMS CED study for MDS).3
Methods
Data sources
Data for this study were acquired from the CIBMTR registry (see
supplemental Section 1 for details).
Patients
Included in this analysis are adult ($55 years) patients with mature
B-, T-, or NK-cell NHL who underwent a first RIC or NMA
conditioning allo-HCT from matched related donors (MRDs),
matched unrelated donors (MUDs), or mismatched unrelated
donors (mmURDs) from 2008 to 2015. Bone marrow and
peripheral blood grafts were included. Patients receiving haploi-
dentical or cord blood transplants were excluded. The analysis was
limited to US transplant centers for generating data in a patient
population relevant to CMS coverage area.
Definition and study end points
The intensity of conditioning regimens was defined using consen-
sus criteria.14 Response to last line of therapy before allo-HCT on
CIBMTR forms is defined using established criteria.15
The primary end point was overall survival (OS); death from any
cause was considered an event, and surviving patients were
censored at last contact. Nonrelapse mortality (NRM) was defined
as death without evidence of lymphoma progression/relapse; relapse
was considered a competing risk. Progression/relapse was defined
as progressive lymphoma after hematopoietic cell transplantation
(HCT) or lymphoma recurrence after a complete remission; NRMwas
considered a competing event. For progression-free survival (PFS), a
patient was considered a treatment failure at the time of progression/
relapse or death from any cause. Patients alive without evidence of
disease relapse or progression were censored at last follow-up.
Acute graft-versus-host disease (GVHD)16 and chronic GVHD17
were graded using standard criteria.
Statistical analysis
Clinical outcomes of the cohort aged $65 years were compared
against the cohort aged 55-64 years. Adjusted probabilities of PFS
and OS were calculated as described previously.18 Adjusted
cumulative incidence of NRM and lymphoma progression/relapse
was calculated to accommodate for competing risks.19 Unadjusted
cumulative incidence of acute/chronic GVHD was calculated.
Associations among patient-, disease-, and transplantation-related
variables and outcomes of interest were evaluated using Cox
proportional hazards regression. A stepwise model-building ap-
proach was used to identify covariates that influenced outcomes.
Covariates with a P , .05 were considered statistically significant.
The proportional hazards assumption for Cox regression was tested
by adding a time-dependent covariate for each risk factor and
each outcome. Covariates that violated the proportional hazards
assumption were added as time-dependent covariates, where the
best cutoff for each time-dependent covariate was determined
using the maximum likelihood method. Interactions between the
main effect and significant covariates were examined (in particular
disease histology, GVHD prophylaxis regimen, and remission status
at HCT); none were found. Results are expressed as relative risks
(RRs). The variables considered in multivariate analysis are shown in
supplemental Table 1. All statistical analyses were performed using
SAS version 9.4 (SAS Institute, Cary, NC).
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Results
Baseline characteristics
Using the CIBMTR database, we identified 1629 NHL patients ($65
years, n5 446; 55-64 years, n5 1183) undergoing a first RIC or NMA
conditioning allo-HCT from 2008 to 2015 in the United States
(Figure 1). The baseline patient-, disease-, and transplantation-related
characteristics are detailed in Table 1. The median patient age was 68
years (range 65-77 years) for the older cohort vs 60 years (range
55-64 years) for the younger cohort. There were no significant
differences between the 2 cohorts in terms of patient gender, race,
Karnofsky performance score (KPS), HCT comorbidity index (HCT-CI),
disease status prior to transplant, time from diagnosis to transplant,
GVHD prophylaxis used, in vivo T-cell depletion, or type of conditioning
regimen(s) used. A higher proportion of patients had undergone a prior
autologous HCT in the younger cohort compared with the older cohort
(38% vs 31%, P 5 .01). Significantly more patients in the younger
cohort underwent an MRD allo-HCT (46% vs 35%, P , .001). The
median follow-up of survivors was 48 months (range 6-98) and 48
months (range 4-101) in the older and younger cohorts, respectively.
Acute and chronic GVHD
The cumulative incidence of grades II-IV acute GVHD at day 180
post–allo-HCT was 38% (95% confidence interval [CI], 35-41) in
the younger cohort vs 35% (95% CI, 31-40) in the older cohort
(P 5 .39) (Table 2). The cumulative incidence of grades III-IV acute
GVHD at day 180 post–allo-HCT was 15% (95% CI, 13-17) vs
17% (95% CI, 14-21), respectively (P 5 .21). The cumulative
incidence of chronic GVHD at 2 years posttransplant in patients
aged 55-64 years was 48% (95% CI, 45-51) compared with 45%
(95% CI, 40-49) in patients aged $65 years (P 5 .25) (Table 2).
NRM and relapse
The adjusted cumulative incidence of NRM at day 100 was 7% in
both groups (P 5 .69) (Table 2). At 1-year posttransplant, the
cumulative incidence of NRM was 15% (95% CI, 13-17) for
the younger cohort vs 18% (95% CI, 15-22) for the older cohort
(P 5 .14). Using multivariate analysis, compared with the younger
cohort, patient age $65 years was associated with a significantly
higher risk for NRM (RR, 1.29; 95%CI, 1.04-1.61, P5 .02; Table 3;
Figure 2A). Independent of patient age, KPS ,90 (RR, 1.52; 95%
CI, 1.24-1.88; P , .0001), HCT-CI $3 (RR, 1.63; 95% CI, 1.27-
2.10; P 5 .0001), and allo-HCT from MUDs and mmURDs (with or
without in vivo T-cell depletion) were associated with a higher risk
for NRM (supplemental Table 2).
The adjusted cumulative incidence of disease progression/relapse
at 4 years was 41% (95% CI, 38-44) in the younger group vs 42%
First Allogeneic Transplant for NHL from
2008-2015 reported to CIBMTR
N7695 patients
Exclude patients:
• Ineligible histologies (N11)
• Cord blood or Haploidentical donors
  (N281)
• Myeloablative conditioning (N654)
• Ex-vivo T-cell depleted transplants (N15)
• Pre-registered cases that did not proceed
  to allogeneic transplantation (N36)
• Cases without informed consent (N222)
• Cases from non-US centers (N414)
• Syngeneic transplants (N41)
• Cases from embargoed centers or centers





Aged  65 years
N=446
Restricted to patients Age 55 years
N3428 patients
Figure 1. Consort diagram.
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(95% CI, 37-47) in the older group and was not significantly
different (P 5 .82) (Table 2). Using multivariate analysis, compared
with the younger cohort, patient age$65 years was not associated
with a significantly increased risk for disease progression/relapse
(RR, 1.02; 95% CI, 0.86-1.22; P 5 .80; Table 3; Figure 2B). Other
independent variables associated with risk for disease progression/
relapse are provided in supplemental Table 2.
PFS and OS
The adjusted 4-year PFS for the younger group was 37% (95% CI,
34-40) vs 31% (95% CI, 26-35) in the older group (P 5 .03)
(Table 2; Figure 3A). Using multivariate analysis, compared with the
younger cohort, patient age $65 years was not associated with a
significantly inferior PFS (RR, 1.11; 95% CI, 0.97-1.27; P 5 .14).
Other independent variables associated with the risk for therapy
failure (inverse of PFS) are provided in supplemental Table 2. The
adjusted 4-year OS for the younger cohort (51%; 95% CI, 48-54)
was not significantly different from the older cohort (46%; 95% CI,
41-51; P 5 .07; Table 2; Figure 3B). Using multivariate analysis,
compared with the younger cohort, patient age $65 years was not
associated with a significantly increased risk for mortality (RR, 1.14;
95% CI, 0.97-1.33; P5 .10) (Table 3). Independent of patient age,
KPS ,90 (RR, 1.34; 95% CI, 1.15-1.56; P 5 .0001), HCT-CI $3
(RR, 1.30; 95% CI, 1.09-1.55; P 5 .003), refractory disease (RR,
1.43; 95% CI, 1.19-1.73; P5 .0002), histology other than follicular
lymphoma and transplantation from an mmURD while using in vivo
T-cell depletion (RR, 1.79; 95% CI, 1.29-2.48; P 5 .0005) were
associated with an increased risk for mortality (supplemental
Table 2).
Subgroup analysis of patients ‡70 years
We performed a subset analysis to evaluate outcomes of patients
who were $70 years old at the time of allo-HCT (n 5 73). Among
this patient population, the cumulative incidence of NRM at 1 year
was 22% (95% CI, 13-32), whereas the cumulative incidence
of progression/relapse at 4 years was 43% (95% CI, 32-54).
Table 1. Baseline patient characteristics of NHL patients aged 55-64





(n 5 446) P
Age at HCT, median (range), y 60 (55-64) 68 (65-77) ,0.001
Male sex, n (%) 773 (65) 303 (68) 0.32
White, n (%) 1099 (93) 421 (94) 0.28
KPS $90, n (%) 720 (61) 257 (58) 0.26
HCT-CI, n (%) 0.41
0 361 (31) 135 (30)
1-2 367 (31) 122 (27)
$3 443 (37) 185 (42)
Missing 12 (1) 4 (,1)
Histology, n (%) 0.02
Follicular lymphoma 273 (23) 82 (18)
Diffuse large B-cell lymphoma 363 (31) 129 (29)
Mantle cell lymphoma 257 (22) 131 (29)
Mature T/NK-cell lymphoma 237 (20) 87 (20)
Others 53 (4) 17 (4)
Interval from diagnosis to HCT, median
(range), mo
33 (1-386) 37 (2-322) 0.59
Disease status prior to HCT, n (%) 0.68
Sensitive 993 (84) 384 (86)
Resistant 179 (15) 59 (13)
Untreated/unknown 11 (,1) 3 (,1)
Prior autologous HCT, n (%) 451 (38) 140 (31) 0.01
Year of HCT, n (%) 0.18
2008-2010 416 (35) 137 (31)
2011-2013 502 (43) 195 (44)
2014-2015 265 (22) 114 (25)
Conditioning regimens, n (%) 0.35
Flu/Bu 6 others 323 (27) 124 (28)
Flu/CY 6 others 162 (14) 55 (12)
Flu/CY/TBI 6 others 64 (5) 30 (7)
Flu/Mel 6 others 311 (26) 109 (24)
TBI 6 others 41 (3) 9 (2)
TBI/Flu 148 (13) 53 (12)
TLI/ATG 67 (6) 36 (8)
Others* 67 (6) 30 (7)
ATG/alemtuzumab in conditioning 323 (27) 130 (29) 0.12
Graft source, n (%) 0.003
Bone marrow 54 (5) 37 (8)
Peripheral blood 1129 (95) 409 (92)
Donor type, n (%) ,0.001
MRD 546 (46) 156 (35)
MUD 508 (43) 241 (54)
mmURD 129 (11) 49 (11)
Donor–recipient sex match, n (%) 0.08
Male–male 502 (42) 216 (48)
Others 674 (57) 226 (51)






(n 5 446) P
Donor–recipient CMV status, n (%) 0.66
D2/R1 270 (23) 122 (27)
Others 744 (63) 266 (60)
Missing 169 (14) 58 (13)
GVHD prophylaxis, n (%) 0.21
CNI 1 MTX 1 other(s) except MMF, post-Cy 572 (48) 201 (45)
CNI 1 MMF 1 other(s) except post-Cy 403 (34) 149 (33)
CNI 1 other(s) except MMF, MTX, post-Cy 134 (11) 56 (13)
Others† 68 (6) 33 (7)
Missing 6 (,1) 7 (2)
Follow-up of survivors, median (range), mo 48 (4-101) 48 (6-98)
ATG, antithymocyte globulin; Bu, busulfan; CMV, cytomegalovirus; CNI, calcineurin
inhibitors; Cy, cyclophosphamide; D, donor; Flu, fludarabine; Mel, melphalan; MMF,
mycophenolate mofetil; MTX, methotrexate; R, recipient; TBI, total body irradiation; TLI, total
lymphoid irradiation.
*16 beam-like; 56 Flu 6 other(s); 25 Mel 6 other(s).
†43 CNI alone; 58 post-Cy 6 other(s).
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The 4-year PFS and OS were 27% (95% CI, 17-38) and 44%
(95% CI, 32-56), respectively.
Cause of death
At last follow-up, there have been 550 (46%) deaths in the 55-
64–year cohort and 232 (52%) deaths in the$65-year cohort. The
most common cause of death in both groups was relapse of the
primary disease (n 5 212 and n 5 79, respectively) (supplemental
Table 3). The next most common cause of death in the 55-64–year
cohort was GVHD (n 5 86), followed by infection (n 5 39). In
contrast, infection was the second most common cause of death in
the $65-year group (n 5 39), followed by GVHD (n 5 32).
Discussion
There is growing awareness that age, by itself, is an insufficient and
often inaccurate determinant of medical fitness for any specific
treatment. In this study, we report allo-HCT outcomes for a large
cohort of (potentially) Medicare-eligible patients aged $65 years
relative to a younger, generally Medicare-noneligible group.
Currently, coverage for allo-HCT in NHL in the United States is
limited to only those states that are in the National Government
Services (NGS) jurisdiction. NGS is a Medicare Administrative
Contractor that makes claims on behalf of CMS. It is plausible that a
small subset included in our study could have undergone HCT
using non-Medicare payers (eg, private insurance, self-pay).
However, because NHL is not a covered CMS indication for allo-
HCT, and the majority of states are not under NGS jurisdiction,
there is significant disparity in the access to allo-HCT in NHL in the
United States.
Through this registry analysis we found no significant difference in
OS between the 2 cohorts, with 46% of patients aged $65 years
still alive at 4 years posttransplantation. Secondly, although there
was a modest, but statistically significant, risk for increased NRM in
the older cohort, this finding did not translate into significant
differences in PFS or OS in multivariate analysis. Additionally, NRM
was identical at 100 days posttransplant, and it was only beyond 1
year posttransplant that the increase in NRM becomes appreciable.
Because the patients in the older cohort were, on average, almost a
decade older, the difference in NRM at 4 years may be partially
attributed to expected age-related mortality. Lastly, there was no
difference in acute or chronic GVHD, and relapse rates were
similar between the 2 groups, suggesting that the efficacy of
Table 2. Probabilities at fixed time points
Outcomes
55-64 years (N 5 1183) ‡65 years (N 5 446)
Pn Probability, % (95% CI) n Probability, % (95% CI)
Acute GVHD (II-IV), 180 d 1108 38 (35-41) 425 35 (31-40) 0.39
Acute GVHD (III-IV), 180 d 1108 15 (13-17) 426 17 (14-21) 0.21
Chronic GVHD, y 1145 438
1 40 (37-43) 35 (31-40) 0.06
2 48 (45-51) 45 (40-49) 0.25
NRM 1183 446
100 d 7 (5-8) 7 (5-10) 0.69
1 y 15 (13-17) 18 (15-22) 0.14
4 y 24 (21-27) 30 (25-35) 0.03
Relapse/progression, y 1183 446
1 30 (27-32) 29 (24-33) 0.70
4 41 (38-44) 42 (37-47) 0.82
PFS, y 1183 446
1 55 (52-58) 53 (49-59) 0.51
4 37 (34-40) 31 (26-35) 0.03
OS, y 1183 446
1 69 (67-72) 67 (62-71) 0.31
4 51 (48-54) 46 (41-51) 0.07
Table 3. Multivariable analysis results
n RR 95% CI P
NRM, y
55-64 1166 1 0.02
$65 436 1.29 1.04-1.61
Progression/relapse, y
55-64 1166 1 0.80
$65 436 1.02 0.86-1.22
PFS, y
55-64 1166 1 0.14
$65 436 1.11 0.97-1.27
OS, y
55-64 1166 1 0.10
$65 436 1.14 0.97-1.33
Detailed results of multivariate analysis are provided in supplemental Table 2.
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transplantation (and possibly graft-versus-lymphoma effect) is
comparable, despite differences in age.
We acknowledge that allo-HCT is not the only therapeutic option
available to older patients with relapsed/refractory or high-risk NHL.
The intent of our analysis is not to prove superiority of allo-HCT in
older NHL patients relative to other available tools (eg, novel agents,
autologous HCT, gene-modified T-cell therapies). Rather, we aim to
demonstrate that, in any given NHL patient $65 years old, if after
consideration of multiple variables the treating physician has
decided that allo-HCT is the next best therapy, an arbitrary age
cutoff and lack of third-party (eg, CMS) reimbursement should
not remain a barrier against transplantation. Our study utilizing a
large contemporary dataset suggests that survival outcomes of
such Medicare-age eligible patients are not dramatically inferior to
a decade-younger patient cohort undergoing similar allo-HCT
procedures.
Although other series have also evaluated the efficacy and toxicity of
allo-HCT in older adults, the number of patients has been much
smaller, and ours is the first to focus singularly on allo-HCT
outcomes of NHL patients aged $65 years. In a prior CIBMTR
analysis of NHL patients aged $40 years who underwent allo-HCT
between 2001 and 2007, the 3-year OS ranged from 39% to 54%,
stratified by age.11 However, among the 1248 NHL patients
included in that CIBMTR analysis, only 82 patients were 65 years or
older. Recently, CIBMTR reported outcomes of patients aged $70
years undergoing allo-HCT for various hematologic malignancies
between 2000 and 2013 and showed improving patient outcomes
in more recent years (2008-2013). The 2-year OS of the study
population transplanted from 2008 to 2013 was 39%, but
outcomes of NHL patients (;10% of study population) were not
reported separately. Among 73 NHL patients aged$70 years in our
report who underwent allo-HCT, the 4-year OS was 44%, which
is encouraging considering the aforementioned data. With the
development of effective in vivo and ex vivo T-cell depletion
approaches (eg, posttransplant cyclophosphamide or TCR-a/b and
CD19 depletion), the utilization of adult alternative donors is rapidly
increasing.20 The CIBMTR12,21 and the European Society for
Blood and Marrow Transplantation22,23 have recently reported that
outcomes of lymphoma patients undergoing haploidentical trans-
plantation are comparable to MRD and MUD allo-HCT. A report
from Johns Hopkins University suggests the feasibility of NMA
haploidentical transplantation in older adults (50-75 years, median
age 61 years) with hematological malignancies.24 An ongoing
CIBMTR study evaluating the role of haploidentical HCT in older
patients will further elucidate its role.
It is important to acknowledge that allo-HCT is applicable only to
the subset of healthy older individuals with few or no serious
medical comorbidities. The importance of appropriate patient
selection for allo-HCT cannot be overemphasized. To help with
decision making in an older population, objective tools, such as
HCT-CI,25 can be useful in making determinations for allo-HCT
candidacy. Our study found, similar to other reports,26 that an
HCT-CT$ 3 negatively impacts OS and PFS. Furthermore, there
are evolving data suggesting that comprehensive perfor-
mance assessment tools may have value when evaluating an























































Figure 2. Adjusted NRM and relapse/progression for allo-HCT in younger













































Figure 3. PFS and OS for allo-HCT in younger and older patients with NHL.
(A) PFS; (B) OS.
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comprehensive geriatric assessment has independent prognos-
tic utility in evaluating older patient candidacy for allo-HCT.27
The effectiveness of such tools will be validated in an upcoming
Blood and Marrow Transplantation Clinical Trials Network study
that intends to incorporate geriatric assessments as part of
the prospective clinical trial. Lastly, disease subtype may play a
role in decision making for allo-HCT in NHL. Although we
included multiple histologies, our multivariate analysis found
that patients with nonindolent subtypes (eg, diffuse large B-cell
lymphoma, mantle cell lymphoma, or NK/T cell lymphoma) had a
higher risk for relapse and worse PFS and OS (supplemental
Table 2).
There are several limitations to this analysis. As a registry study, our
analysis is limited to the information available in the database.
Although we aimed to adjust for possible confounders with our
multivariate analysis, unmeasured variables could influence our
findings. Although the benefit of allo-HCT in elderly NHL patients
(relative to other treatment options) can only be established via
prospective randomized studies, these are logistically challenging
and unlikely to be performed. Another limitation is the inherent bias
in only evaluating transplanted patients. Patients who are eligible to
undergo allo-HCT represent a select population that is healthy
enough with responding disease to be candidates for transplant; as
a result, our findings are not applicable to all elderly patients with
NHL. Because we did not include cord or haploidentical donors, our
results are not applicable to those groups. Lastly, there were
differences in the use of autologous transplant prior to allo-HCT
between the 2 groups. Although it is difficult to elucidate the
etiology of this difference in a registry study, we speculate that this
may be due to poorer mobilization in older adults and/or center
practices to avoid high-dose chemotherapy in patients aged $65
years.
In conclusion, for NHL patients who are eligible for allo-HCT, there
was no difference in OS for patients aged 55-64 years compared
with patients aged$65 years. These data strongly support that age
alone should not be a determinant for allo-HCT eligibility in NHL.
The role and relative benefit of allo-HCT in NHL will undoubtedly
evolve in the coming years with the advent of new cellular and
targeted therapies; however, for now, allo-HCT represents an
opportunity for cure in patients without other options and should be
available to all suitable candidates regardless of age and insurance
coverage. We hope that the data from this study will provide the
direct evidence needed to justify modification of the current
Medicare national coverage determination to allow for allo-HCT
in NHL.
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8. Dreger P, Döhner H, Ritgen M, et al; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic
lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438-2447.
9. Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort
analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2013;19(4):625-631.
10. Robinson SP, Boumendil A, Finel H, et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous
transplant achieves durable long term disease control. An analysis from the LymphomaWorking Party of the EBMT. Ann Oncol. 2016;27(6):1088-1094.
11. McClune BL, Ahn KW, Wang HL, et al. Allotransplantation for patients age $40 years with non-Hodgkin lymphoma: encouraging progression-free
survival. Biol Blood Marrow Transplant. 2014;20(7):960-968.
12. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched
unrelated donors. Blood. 2016;127(7):938-947.
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